Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy.
By M. Tumbarello, P. Viale, C. Viscoli, E. Trecarichi, F. Tumietto, A. Marchese, T. Spanu, S. Ambretti, F. Ginocchio, F. Cristini and 4 more. Clinical Infectious Diseases, 2012
971 citations recorded by the source corpus.
Subfields: Clinical Biochemistry, Critical Care and Intensive Care Medicine, Molecular Medicine
View Paper: https://www.semanticscholar.org/paper/720aca691329d1efb5506816ad260f1e4e09eaf6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Clinical Biochemistry
In Molecular Medicine
Citations in the corpus
- The Minimum Inhibitory Concentration of Antibiotics: Methods, Interpretation, Clinical Relevance (2021, background): “With 8 < MIC values ≤ 32 mg/L, it is necessary not only to apply high doses, but also to combine it with at least two other antibiotics [56].”
- Global Dissemination of Carbapenemase-Producing Klebsiella pneumoniae: Epidemiology, Genetic Context, Treatment Options, and Detection Methods (2016, background): “…including a carbapenem, such as a combination of tigecycline, colistin, and meropenem, was strongly effective in the treatment of KPC-producing K. pneumoniae, including colistinresistant isolates (Tumbarello et al., 2012, 2015; Giamarellou et al., 2013; Hong et al., 2013; Daikos et al., 2014).”
- Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance (2015, methodology): “Treatment regimens using carbapenems may be an option when the MICs of carbapenems are 8 mg/liter when a second antibiotic is added or when a prolonged intravenous infusion regimen is used (123, 124).”